Study in Healthy Subjects to Examine the Safety and Tolerability of ACT-1004-1239 Given as Multiple, Gradually Increasing Doses and to Examine the Effects of ACT-1004-1239 on the Body and the Way the Body Takes up, Distributes, and Gets Rid of ACT-1004-1239
Clinical trial NCT04286750 · COMPLETED
Trial details
- NCT number
- NCT04286750
- Sponsor
- Idorsia Pharmaceuticals Ltd.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-07-11
- Primary completion
- 2020-09-25
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.